remibrutinib
novartis
['remibrutinib']
plenary:
remibrutinib (lou064) a btk inhibitor in sjogren s favourable safety profile well-tolerated over 24 wks improved essdai, salivary flow, igs may be first effective oral disease-modifying therapy for ss
dorner t abs1113 #acr22 
MD PhD Consultant Rheumatologist &Physician,Assoc Medical Director,Digital Leader,NASS Trustee &Best Rheum Care,Visiting Fellow Henley Business School,ExecCoach